 |
Jeffrey G. Carr, M.D., F.A.C.C.
Address
115 West Fifth Street
Tyler, TX 75701
Telephone: (903) 595-2283
Fax: (903) 597-2238
Cardiology Practice
- 1994 - Present: Cardiovascular Associates of East Texas, P.A., Tyler, Texas
Education
Academic Degrees
- 1984 – 1988: University of California, Los Angeles, School of Medicine - Doctor of Medicine
- 1979 – 1983: University of California, Los Angeles, Bachelor of Science - Psychobiology
Post Graduate Training
Residency and Internship
- 1988 - 1991: Internal Medicine, UCLA Medical Center
Cardiology Fellowships
- 1993 – 1994: Interventional Cardiology Fellowship, UCLA Medical Center
- 1991 – 1994: Cardiology Fellowship, UCLA Medical Center
Board Certification
- 2000: Diplomate, American Board of Internal Medicine – Interventional Cardiology
- 1995: Diplomate, American Board of Internal Medicine – Cardiovascular Disease
- 1991: Diplomate, American Board of Internal Medicine
Medical Licensure
- Texas State License, J6892
- California State License, G067021
Hospital Appointments
- 2003 – Present: Consulting – Texas Spine and Joint
- 2001 – Present: Consulting – East Texas Medical Center Carthage, Texas
- 2001 – Present: Courtesy/Non-Active – Trinity Mother Frances Hospital, Jacksonville, Texas
- 1997 – Present: Consulting - Laird Memorial Hospital, Kilgore, Texas
- 1997 – Present: Consulting - East Texas Medical Center Hospital, Jacksonville, Texas
- 1994 – Present: Consulting - East Texas Medical Center Hospital, Athens, Texas
- 1994 – Present: Consulting - East Texas Medical Center Hospital, Crockett, Texas
- 1994 – Present: Consulting - East Texas Medical Center Hospital, Quitman, Texas
- 1994 – Present: Active Staff - East Texas Medical Center Hospital, Tyler, Texas
- 1994 – Present: Active Staff - Trinity Mother Frances Hospital, Tyler, Texas
Professional Societies, Activities and Other Memberships
- 2009 – Present: Tyler Cardiac and Endovascular – Medical Director and Governing Board
- 2007 – Present: Smith County Medical Society – Editorial Board and Guest Editor
- 2007 – Present: American College of Phlebology - Member
- 2005: Testified to the Federal Trade Commission regarding Johnson-Johnson and Guidant Corporations’ Merger – Anti-trust issues.
- 2005 – Present: Texas Chapter American College of Cardiology – Council Member
- 2005 – Present: Medtronic Corporation – Peripheral Clinical Advisory Board
- 2005 – Present: Boston Scientific Corporation – Physician Advisory Board
- 2004 – Present: Bethesda Health Clinic – Healthcare Program to the Uninsured – Board of Directors
- 2003 – 2005: Medical Executive Committee- Trinity Mother Frances Hospital, Tyler, Texas
- 1999 – 2000: Credentials Committee – East Texas Medical Center
- 1997 – 2007: Director of Research – Cardiovascular Associates of East Texas
- 1997 – 2001: Director - Heart Care Partnership - East Texas Medical Center
- 1997 – 2001: Director of Research - East Texas Medical Center Cardiovascular Institute
1997 – 1998: President - American Heart Association - Smith County
- 1996 – 2003: Lipid Clinic Director - Cardiovascular Associates of East Texas
- 1996 – Present: Director of Clinical Services – Cardiovascular Associates of East Texas
- 1996 – Present: Fellow, American College of Cardiology
- 1994 – Present:
- American Heart Association - Smith County - Board of Directors
- American College of Cardiology
- American Medical Association
- Texas Medical Association
- Smith County Medical Society
- 1993: UCLA Medical Center - Managed Care Committee
- 1989 – 1994: UCLA Coronary Care and Cardiac Observation Unit Committees
- Past:
- California Medical Society
- American College of Physicians
- Christian Medical Society
- American Society of Echocardiography
- Arteriosclerosis and Thrombosis - Manuscript Reviewer
- American Journal of Cardiology - Manuscript Reviewer
Publications
- Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr JG, et. al. Long-term Efficacy of Bivalirudin and Provisional Glycoprotein Iib/IIIa Blockade vs. Heparin and Planned Glycoprotein Iib/IIIa Blockade During Percutaneous Coronary Revascularization REPLACE –2 Randomized Trial. Journal of the American Medical Association 2004;292:696-703
- Carr JG, Stevenson LW, Walden J, Heber D: Prevalence and hemodynamic correlations of malnutrition in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American J. Cardiology 1989; 63; 709-713
- Carr JG, Johnson JA, Kobashigawa JA, Sack JB, Yeatman LA: Does the vasodilator response to nitroglycerin over time affect quantitative assessment of coronary artery lesion dimensions using intravascular ultrasound? J. of the American College of Cardiology 1994; SI:243A
- Carr JG, Miller L, Anderson TF, Murali S, Ventura H, Gordon J, Wilensky R, Yeung AC: Does steroid-free immunosuppression influence the degree of intimal thickening after heart transplantation? A multicenter Study, Circulation, 1994;90:638A
- Kobashigawa JA, Gleeson MP, Stevenson LW, Carr JG, Moriguchi JD, Kawata N, Hamilton MA, Hage A, Drinkwater D, Laks H: Prevention of severe cardiac allograft rejection with Pravastatin: A randomized trial. Journal of the American College of Cardiology 1994;SI:483A
- Johnson JA, Kobashigawa JA, Yeatman L, Carr JG, Trosian KD, Sabad A, Wener LS, Drinkwater D, Laks H: Does pre-existing donor heart atherosclerosis lead to more transplant coronary artery disease? A prospective study using morphometric analysis of intracoronary ultrasound. Journal of American College of cardiology, 1996;2:144A
- Johnson JA, Kobashigawa JA, Yeatman L, Carr JG, Trosian KD, Sabad A, Wener LS, Drinkwater D, Laks H. The distribution and characteristics of transplant coronary disease in a prospective morphometric analysis of intracoronary ultrasound. Journal of American College of Cardiology, 1996:27A
Research
- Co-Investigator - PLATO Study - A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS).
- Co-Investigator - XIENCE™ V: Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.
- Principal Investigator – LEAP -- A Two Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Simvastatin, Losartan, and Pioglitazone on Cardiovascular disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients with Peripheral Artery Disease.
- Principal Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.
- Co-Investigator – RE-LY - Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.
- Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.
- Co-Investigator - ACCOMPLISH- A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.
- Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidrogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).
- Co-Investigator – VISION 305 Study - “Vasodilator Induced Stress In Concordance with Adenosine” A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.
- Co-Investigator - APEX-AMI Study - “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.
- Principal Investigator – ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome without ST-segment elevation.
- Principal Investigator - REPLACE II - A Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events, Part 2: REPLACE-2 (TMC-BIV-01-03)Principal Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
- Principal Investigator – Otsuka Protocol 21-98-214-01 CASTLE “ A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease”.
- Principal Investigator – GUSTO IV ACS – A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of ReoPro™, Given as a Bolus Followed by a 24- or 48-Hour Infusion, for the Treatment of Acute coronary Syndrome Without ST-Segment Elevation.
- Principal Investigator – Left Main IVUS Registry – Scripps Clinic – A multicenter prospective registry designed to determine the value of diagnostic IVUS in the setting of an inconclusive coronary angiogram.
- Principal Investigator - PRAISE 2 - (Prospective Randomized Amlodipine Survival Evaluation -2) Phase III Protocol NO. 053-185: A randomized, double-blind, dose-titration, parallel group, placebo-controlled study to evaluate the effect of Amlodipine on survival in patients with congestive heart failure.
- Principal Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.
- Principal Investigator - ATLAS Trial (Aspirin TicLid vs Anticoagulation for Stents) - George Washington University, Cardiovascular Research Institute.
- Principal Investigator - Niaspan Trial #MA-97-0101 Phase IV: an open-label, community-based clinical practice study of Niaspan in patients with hyperlipidemia.
- Principal Investigator - Intravascular Ultrasound Core Imaging Laboratory (Syntax MUCS1864 TCAD) Randomized, double-blind comparative study of Mycophenolate Mofetil or Azathioprine each in combination with Cyclosporine and corticosteroids for the prevention of rejection in cardiac allograft recipients.
- Co-Investigator – A Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina
- Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy “AMIHOT” Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
- Co-Investigator – SYNERGY - A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes (ACS).
Aventix Pharmaceuticals Protocol Number ENO.GMA.301. IND# 31532
- Co-Investigator-INSPIRE :A Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi Single Photon Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.
- Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone: CordaroneÒ I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US
- Co-Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparision of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
- Co-Investigator – CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease. To Monitor inflammatory markers
- Co-Investigator – ER TIMI 19 – A Phase IV Open-Label Trial of Prehospital Administration of Retavaseâ for ST elevation MI – the Early Retavaseâ (ER)-TIMI 19 Trial.
- Co-Investigator – STEP AMI – An Open Study, with Blinded Endpoint Assessment, to Assess the Safety, Tolerability and the Effect on Coronary Artery Patency of Intravenous AR-C69931MX as both Monotherapy and Adjunct to Activase in Patients with ST-elevation Myocardial Infarction.
- Co-Investigator – MICCAT ( MICardis Community Access Trial) An Phase IV – Open label evaluation of the effectiveness of Micardisâ ( telmisartan) on blood pressure control and quality of life in patients with essential hypertension.
- Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
- Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
- Co-Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction.
- Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A phase III, randomized, open-label trial evaluating the efficacy and safety of ReoProTM (ABCIXIMAB) in combination with reduced dose RetavaseTM / RapilysinTM (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
- Co-Investigator - Paragon B Trial: A randomized, double-blind, placebo-controlled study of Lamifiban (RO44-9883) in patients with unstable angina/non
Q wave myocardial infarction.
- Co-Investigator - PACT trial (Plasminogen-Activator Angioplasty Compatibility Trial) A randomized, double-blind placebo controlled study assessing clinical efficacy of bolus infusion TPA to placebo in acute MI patients with rescue angioplasty.
- Co-Investigator - Coumadin, Aspirin and Reinfarction Study; “CARS” Dup 647-003-459. A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
- Co-Investigator - CARS (Coumadin, Aspirin and Reinfarction Study) EKG Substudy Dup647-003-459. A randomized, double-blind study to compare the efficacy and safety of fixed low doses of Coumadin plus aspirin to aspirin alone in the prevention of reinfarction, cardiovascular death, and stroke in post-myocardial infarction patients.
- Co-Investigator - CardioGenesis Transmyocardial Revascularization (TMR) System: To evaluate the safety and efficacy of the CardioGenesis TMR System when used for TMR performed as an adjunct to CABG in patients with angina resulting from coronary artery disease which is only partially treatable by CABG.
- Co-Investigator - TMR012-A. A Single-Blind Randomized Study of the Safety and Effectiveness of Percutaneous Transluminal Myocardial Revascularization (PTMR) Performed with the Eclipse Holmium Laser as an Adjunct to Percutaneous Coronary Intervention
- Co-Investigator - IMDUR (Isosorbide Mononitrate) Patient Acceptability Program. A study comparing the efficacy, safety and ease of use of three FDA-approved formulations; IMDUR, ISDN, and ISMO. The study design assesses if patients with stable angina pectoris benefit in terms of fewer anginal attacks, increased exercise tolerance, simplicity and convenience of use.
- Clinical Investigator - Multicenter trial prospectively evaluating the natural history of transplant coronary artery disease (TCAD) assessed by intravascular ultrasound (IVUS).
- Randomized trial on the effects of lipid lowering with Pravastatin on cardiac transplant rejection and TCAD assessed by IVUS.
- Co-Investigator - (NRMI) National Registry for Myocardial Infarction.
- Co-Investigator - Extra Point. Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System
Honors/Awards
- Internal Medicine Honors
- Phi Beta Kappa
- Magna Cum Laude
- Blue Key National Honor Fraternity
- 1991 - 1992: UCLA Medical Center’s Outstanding Teacher (Fellow)
- 1991 - 1992: UCLA (Nurses’) Physician of the Year
Professional Qualifications/Certifications/Interests
|
About
Us 